Home/Filings/4/0001127602-25-003957
4//SEC Filing

Murphy Nicole 4

Accession 0001127602-25-003957

CIK 0000875045other

Filed

Feb 9, 7:00 PM ET

Accepted

Feb 10, 6:47 PM ET

Size

15.6 KB

Accession

0001127602-25-003957

Insider Transaction Report

Form 4
Period: 2025-02-06
Murphy Nicole
Head of Pharm Ops and Tech
Transactions
  • Exercise/Conversion

    Common Stock

    2025-02-07+2,10211,736.374 total
  • Tax Payment

    Common Stock

    2025-02-07$141.35/sh620$87,63711,116.374 total
  • Exercise/Conversion

    Common Stock

    2025-02-07+1,94013,056.374 total
  • Tax Payment

    Common Stock

    2025-02-07$141.35/sh603$85,23412,453.374 total
  • Exercise/Conversion

    Restricted Stock Unit

    2025-02-071,9403,880 total
    Exercise: $0.00Exp: 2027-02-07Common Stock (1,940 underlying)
  • Award

    Restricted Stock Unit

    2025-02-06+14,05014,050 total
    Exercise: $0.00Exp: 2028-02-06Common Stock (14,050 underlying)
  • Exercise/Conversion

    Restricted Stock Unit

    2025-02-072,1022,102 total
    Exercise: $0.00Exp: 2026-02-08Common Stock (2,102 underlying)
Footnotes (3)
  • [F1]The restricted stock units vest in three equal yearly installments beginning on the first anniversary of the grant date of February 6, 2025.
  • [F2]The restricted stock units vest in three (3) equal annual installments commencing one year after the grant date of 02/8/2023.
  • [F3]The restricted stock units vest in three (3) equal annual installments, commencing one year after the grant date of 02/07/2024.

Issuer

BIOGEN INC.

CIK 0000875045

Entity typeother

Related Parties

1
  • filerCIK 0001910644

Filing Metadata

Form type
4
Filed
Feb 9, 7:00 PM ET
Accepted
Feb 10, 6:47 PM ET
Size
15.6 KB